Azelaprag

BioAge Labs presents preclinical data for apelin receptor agonist azelaprag for obesity demonstrating significant improvements in weight loss and body composition when combined with incretin drugs.
Azelaprag is an orally available small molecule agonist of the apelin receptor APJ. Apelin is an exercise-induced signaling molecule (exerkine) that acts on APJ to mediate many of the metabolic benefits of physical activity.